About the job
Join Evidence Action as a Consultant for the Syphilis-Free Start Program
At Evidence Action, we implement data-driven interventions aimed at fundamentally improving lives on a large scale. We tackle neglected global health challenges and provide validated solutions to create healthier futures for generations to come.
Our operational model translates the latest academic research, including insights from Nobel Prize-winning economists, into tangible outcomes. We rigorously measure progress and results at every phase to ensure a significant impact on individuals living in poverty and those affected by preventable or treatable health conditions. With operations in nine countries and a dedicated team of over 900, we have reached more than 500 million people, collaborating closely with governments to scale our effective interventions.
Key Achievements:
- Our Deworm the World initiative has provided over 2 billion treatments, drastically reducing worm prevalence and generating more than $23 billion in lifetime productivity gains.
- Through the Safe Water Now program, we have saved the lives of over 15,000 children.
- Our Accelerator project explores novel opportunities in global health, testing low-cost interventions with high potential for saving and improving lives.
About the Syphilis-Free Start Program
The Syphilis-Free Start (SFS) Program partners with Ministries of Health to enhance syphilis screening and treatment among pregnant women, aiming to prevent mother-to-child transmission of syphilis. By leveraging investments in HIV, we seek to bridge the gaps in syphilis screening through the implementation of HIV/syphilis dual testing, as well as address treatment barriers for pregnant women who test positive for syphilis.
Since its inception in Liberia in 2020, our program has successfully increased syphilis screening rates from 7% to 88% over 3.5 years, with 94% of syphilis-positive pregnant women now receiving treatment. Following our technical assistance, the Liberian Ministry of Health has secured the national supply of dual tests and benzathine penicillin. We have expanded our efforts to Zambia, Cameroon, and Côte d’Ivoire, achieving remarkable outcomes, including a rise in syphilis screening from 45% to 75% in Zambia within the first year of scale-up.